{
    "clinical_study": {
        "@rank": "144616", 
        "arm_group": {
            "arm_group_label": "AVE8062 / Docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To determine the dose limiting toxicity (DLT), the maximum administered dose (MAD) and the\n      maximum tolerated dose (MTD) of AVE8062 and docetaxel in combination administered\n      sequentially on D1 & D2 respectively every 3 weeks in patients with advanced solid tumors.\n\n      Secondary Objectives:\n\n        -  To define the overall safety profile of the combination.\n\n        -  To characterize the pharmacokinetic (PK) profile of AVE8062 and docetaxel when\n           administered in combination.\n\n        -  To evaluate anti-tumor activity of the combination.\n\n        -  To evaluate potential predictive biomarkers.\n\n      The study includes a tumoral pharmacogenomic sub-study conducted in a subset of sites. The\n      objective to analyse a set of biological biomarkers in order to identify a potential\n      predictive signature of efficacy for AVE8062 in combination with docetaxel."
        }, 
        "brief_title": "Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Neoplastic Disease", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The duration of study for each patient will include 4-week screening phase prior to first\n      inclusion of study drug, 21-day study treatment cycles, end of treatment visit and follow-up\n      phase.  Each patient will be treated until disease progression, unacceptable toxicity or\n      other study discontinuation criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Advanced neoplastic disease (i.e metastatic or locally advanced disease) for which\n             docetaxel-based regimen therapy is indicated such as breast, non-small cell lung and\n             prostate cancer.\n\n          -  ECOG performance status of 0 to 1.\n\n        Exclusion criteria:\n\n          -  Concurrent treatment with any other anticancer therapy.\n\n          -  Patient with locally advanced or metastatic breast cancer who never received adjuvant\n             chemotherapy.\n\n          -  Brain metastases and carcinomatous leptomeningitis.\n\n          -  Prior intensive chemotherapy with autologous stem cell rescue.\n\n          -  Patients who received a high cumulative dose of anthracycline (i.e doxorubicin >\n             400mg/m2 or epirubicin >750 mg/m2).\n\n          -  Impaired cardiovascular function.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907685", 
            "org_study_id": "TCD6295", 
            "secondary_id": "2005-005027-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "AVE8062 / Docetaxel", 
                "description": "Pharmaceutical form:Solution for infusion\nRoute of administration: Intravenous", 
                "intervention_name": "AVE8062", 
                "intervention_type": "Drug", 
                "other_name": "Ombrabulin"
            }, 
            {
                "arm_group_label": "AVE8062 / Docetaxel", 
                "description": "Pharmaceutical form: solution for infusion\nRoute of administration: Intravenous", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "XRP6976"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 22, 2013", 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants With Dose Limiting Toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks (cycle 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907685"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to  disease progression or unacceptable toxicity or study discontinuation criteria (median treatment of 4 cycles)"
            }, 
            {
                "measure": "Plasma concentration of AVE8062 and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "Before AVE8062 infusion, immediately prior to the end of AVE8062 infusion, 5, 10, 25, 45 and 60 minutes then 2, 4, 6, 8-10 and 24 hours post AVE8062 infusion (cycle 1)"
            }, 
            {
                "measure": "Plasma concentration of docetaxel", 
                "safety_issue": "No", 
                "time_frame": "Before docetaxel infusion (corresponding to 24 hours post AVE8062 infusion), 15 minutes before the end of docetaxel infusion, 15 and 45 minutes post docetaxel infusion (cycle 1)"
            }, 
            {
                "measure": "Response evaluation criteria in solid tumors (RECIST) defined objective response", 
                "safety_issue": "No", 
                "time_frame": "Up to  disease progression or unacceptable toxicity or study discontinuation criteria (median treatment of 4 cycles)"
            }, 
            {
                "measure": "Biomarkers expression profile of each patient in order to identify preliminary correlation with antitumor activity of the combination treatment in patients with available pre-treatment biopsy", 
                "safety_issue": "No", 
                "time_frame": "End of treatment or until disease progression or unacceptable toxicity or study discontinuation criteria"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}